This article was originally published in The Tan Sheet
Fred Razzaghi assumes role of director-technical affairs in CHPA's Science & Technology department, trade group announces Dec. 6. Responsibilities include serving as "staff executive to committees, subcommittees and task groups relating to technical aspects of quality production of OTCs," managing meetings for the OTC technical community and serving as liaison to outside organizations, CHPA notes. Razzaghi brings over 20 years of domestic and international experience in quality control and manufacturing, having worked for firms such as GSK, Wyeth and Carter-Wallace...
You may also be interested in...
COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.
Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.
‘Hunker Down, Expect The Worst And Hope For The Best’: Investment Analyst Advises Medtech Businesses To Cut Costs
Maxim Jacobs, managing partner at Edison Investment Research, urges medtech companies to be financially prudent as the COVID-19 pandemic worsens. Cancellations of routine surgeries are creating a huge strain on device businesses which could continue for months.